This meta‐analysis of 38 randomized clinical trials, involving over 16 000 participants with T2D, demonstrated that newer incretin mimetics, particularly s.c. semaglutide and tirzepatide, provide greater reductions in HbA1c, FPG and body weight compared with earlier‐generation GLP‐1 RAs such as exenatide and lixisenatide. Here, GCG is linked to type 2 diabetes mellitus.